Skip to content
AnalystLens

CADENCE DESIGN SYSTEMS INC 8-K Report, Corporate Update (Sep 1, 2022)

Reports
Other Events·Exhibits & Filings
Filing Date
Filed September 1, 2022
Period End
August 31, 2022
Security
CDNS
In the record · 2016–202610-K1210-Q328-K98

CDNS filed 12 annual reports (10-K), 32 quarterly reports (10-Q) and 98 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Feb ’16Feb ’16
  2. Leadership change8-K · Jul ’21Jul ’21
  3. Leadership change8-K · May ’26May ’26

Summary

Summary of the 8-K filed September 1, 2022. Cited figures are marked; the original filing is the authoritative source.

Cadence Design Systems, Inc. (CDNS) announced the completion of its acquisition of OpenEye Scientific Software Inc. on August 31, 2022.

This strategic move integrates OpenEye's advanced computational molecular modeling and simulation software, crucial for drug discovery in the pharmaceutical and biotech sectors, into Cadence's existing offerings. The acquisition was financed through a mix of existing cash reserves and draws from its senior unsecured revolving credit facility.

Key Highlights

  1. Cadence Design Systems has acquired OpenEye Scientific Software Inc.
  2. OpenEye specializes in computational molecular modeling and simulation software for drug discovery.
  3. The acquisition targets the pharmaceutical and biotech industries.
  4. The transaction was completed on August 31, 2022.
  5. Funding for the acquisition came from cash on hand and credit facility borrowings.
  6. This acquisition expands Cadence's capabilities in life sciences and drug discovery markets.

Frequently Asked Questions

  1. What is the strategic importance of acquiring OpenEye Scientific Software?

    The acquisition of OpenEye Scientific Software allows Cadence to significantly enhance its presence in the rapidly growing life sciences market, particularly in drug discovery. By integrating OpenEye's specialized molecular modeling and simulation software, Cadence can offer more comprehensive solutions to pharmaceutical and biotech companies.

  2. How was the acquisition funded?

    The acquisition was financed using a combination of Cadence's existing cash on hand and borrowings made under its senior unsecured revolving credit facility.

  3. What does OpenEye Scientific Software do?

    OpenEye Scientific Software is a leading provider of computational molecular modeling and simulation software. This technology is vital for pharmaceutical and biotech companies engaged in the process of discovering new drugs.

  4. When did the acquisition officially close?

    The acquisition was completed on August 31, 2022.